Feuerstein's Biotech Mailbag

Welcome to the "biotech mailbag." I get a lot of great reader email and feedback -- keep the email coming -- which I try hard to answer directly. But often, there are questions asked or issues raised that could benefit a wider audience.

So consider this weekly column a chance to ask me questions about biotech or take me to task for something I wrote. I'll pick the best of the mail and address it here. Now, off to the mailbag.

---

This week's topics include Exelixis(EXEL Quote), new hepatitis C drugs, Introgen Therapeutics(INGN Quote) and Alzheimer's. Let's get to it. ...